Rxsight vs Neuronetics
Rxsight and Neuronetics are similar in size: $134m and $149m of revenue in their latest fiscal years. Neuronetics grew faster (99.2% against -3.9%). Neuronetics kept more of each dollar of sales as profit: a net margin of -26.1% against -29.0%. Rxsight carries less debt relative to equity (0.0% against 312.8%).
| Latest fiscal year | RxsightRXST, 2025 | NeuroneticsSTIM, 2025 |
|---|---|---|
| Revenue | $134m | $149m |
| Revenue growth | -3.9% | 99.2% |
| Net income | −$38.9m | −$39.0m |
| Operating margin | -35.8% | -21.1% |
| Net margin | -29.0% | -26.1% |
| Return on equity | -14.0% | -155.7% |
| Free cash flow | −$19.3m | −$21.2m |
| Cash | $19.9m | $28.1m |
| Total debt | $0 | $70.0m |
| Debt to equity | 0.0% | 312.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 461 | 658 |
| Market value | $192m | $171m |
| Price vs our value range | — | — |
| Moat score | 27 (Weak) | 26 (Weak) |
| Insider trades, 12 months | 0 buys, 4 sales | 15 buys, 11 sales |